The $300 million trial between Dakota Access Pipeline developer and Greenpeace reached the halfway mark on Monday as the company wrapped up its side of the case. Energy Transfer claims Greenpeace ...

Novartis plans to acquire Avidity Biosciences to add RNA therapeutics to its neuroscience biz to target rare genetic ...

According to the agreement, Avidity ( NASDAQ: RNA) shareholders will receive $72 a share in cash, a 46% premium to Friday’s ...

An update from PYC Therapeutics Limited ( ($AU:PYC) ) is now available. PYC Therapeutics Limited announced significant progress in its drug ...

Learn more about whether AbbVie Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia ...

Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion  Avidity ...

Chromatin Bioscience is pleased to announce an ongoing research collaboration with Purespring Therapeutics, a precision nephrology company leading the development of targeted, first-in-class genetic ...

Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb: Hamburg, Germany Tuesday, October 28, 2025, 15:00 Hrs [IST] Evotec SE, a life science ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that me ...

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.